Shah, Y.B.; Shaver, A.L.; Beiriger, J.; Mehta, S.; Nikita, N.; Kelly, W.K.; Freedland, S.J.; Lu-Yao, G.
Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review. Cancers 2022, 14, 3773.
https://doi.org/10.3390/cancers14153773
AMA Style
Shah YB, Shaver AL, Beiriger J, Mehta S, Nikita N, Kelly WK, Freedland SJ, Lu-Yao G.
Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review. Cancers. 2022; 14(15):3773.
https://doi.org/10.3390/cancers14153773
Chicago/Turabian Style
Shah, Yash B., Amy L. Shaver, Jacob Beiriger, Sagar Mehta, Nikita Nikita, William Kevin Kelly, Stephen J. Freedland, and Grace Lu-Yao.
2022. "Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review" Cancers 14, no. 15: 3773.
https://doi.org/10.3390/cancers14153773
APA Style
Shah, Y. B., Shaver, A. L., Beiriger, J., Mehta, S., Nikita, N., Kelly, W. K., Freedland, S. J., & Lu-Yao, G.
(2022). Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review. Cancers, 14(15), 3773.
https://doi.org/10.3390/cancers14153773